Cengiz AYDIN, Gül Sevim SAYDAM, Nuray YAZIHAN, Hatice SELÇUK, Ahmet TEMİZHAN

Metabolik sendromda paraoksonaz-1 aktivitesi ve koroner arter hastalığı ilişkisi

Paraoksonaz-1 kalsiyum bağımlı antioksidan bir enzimdir. Paraoksonaz-1’in HDL yapısında bulunduğunun anlaşılmasından sonra koroner arter hastalığı ile ilişkisine yönelik çalışmalar artmıştır. Metabolik sendrom kriterlerinden biri olan dislipidemi koroner arter hastalığı için de risk faktörlerinden biridir. Amacımız metabolik sendromlu hastalarda Paraoksonaz-1 aktivitesini belirleyerek, metabolik sendromlu kişilerde koroner arter hastalığı ile ilişkisini araştırmak, paraoksonaz-1 aktivitesinin HDL, trigliserid ve oksidatif stres’in biyokimyasal göstergelerinden malondialdehid ile korelasyonunu göstermektir. Çalışmamızda ‘Uluslararası Diyabet Derneği’ kriterlerine göre metabolik sendrom tanısı alan 100 hasta ve 26 sağlıklı kişinin örnekleri değerlendirildi. Metabolik sendromlu hastalarda sağlıklı kontrol grubuna göre paraoksonaz-1 aktivitesi istatistiksel olarak anlamlı düşük (p

Anahtar Kelimeler:

Trigliseridler, Malondialdehit, Metabolik sendrom X, Koroner arter hastalığı, Oksidatif stres, Arildialkilfosfataz

Paraoxonase-1 activity in the metabolic syndrome and its relationship with coronary artery disease

Human serum paraoxonase-1 (PON-1) is a calciumdependent antioxidant enzyme. After it was understood that PON-1 is found in the structure of HDL, a number of studies related to its correlation with coronary artery disease (CAD) has increased. One of metabolic syndrome (MS) criteria is dyslipidemia. It is also a risk factor for CAD. Our aim is to evaluate activity of PON-1 in patients with metabolic syndrome, to explain its relationship with HDL, triglyceride (TG) and malondialdehyde (MDA) which is one of the biochemical parameters of oxidative stress. Our study was carried out with 26 healthy subjects and 100 metabolic syndrome patients according to the definition of the International Diabetes Federation. We found significantly lower PON-1 activity and higher MDA levels in the serums of MS patients (p<0.05) compared to healthy subjects. MS patients with CAD have lower levels of PON-1 activity and higher levels of MDA compared to MS patients without CAD (p<0.05). There was not any correlation between PON-1 activities and HDL levels (p>0.05, r=0.15), also between PON-1 and TG levels (p>0.05, r=0.14) of MS patients. As a result; we concluded that PON-1 activity may be used as CAD criteria in MS patients.

Keywords:

Triglycerides, Malondialdehyde, Metabolic Syndrome X, Coronary Artery Disease, Oxidative Stress, Aryldialkylphosphatase,

PDF

___

1. Mackness MI. Possible medical significance of human serum paraoxonase 1989: 202–13
2. Mackness MI, Hallam SD, Peard T, Warner S, Walker CH. The separation of sheep and human serum “A-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol B 1985;82: 675-77.
3. Mc Elveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32: 671–73.
4. Ayub A, Mackness MI, Arrol S, Mackness M, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19: 330–35.
5. Fuhrman B, Volkova N, Aviram M. Paraoxonase 1 is present in postprandial chylomicrons. Atherosclerosis 2005;180: 55–61.
6. Deakin S, Moren X, James RW. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005;179: 17–25.
7. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152–54.
8. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7: 69–76.
9. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier ChL, et al. Human serum paraoxonase is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26: 892–904.
10. Trevisan M, Liu J, Bahsas FB, Menotti A. A syndrome X and mortality: a population-based study. Am J Epidemiol 1998;148: 958–66.
11. International Diabetes Federation. Worldwide definition of the metabolic syndrome. Accessed August 24, 2005.
12. Senti M, Tomas M. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003;88: 5422–26.
13. Eckerson HW, Romson J, Wyte CM, La Du BN. Human serum paraoxonase polymorphism: identification of phenotypes by their responses to salts. Am J Hum Genet 1983;35: 214-27.
14. Gülcü F, Gürsu F. Paraoksonaz ve Aril Esteraz Aktivite Ölçümlerinin Standardizasyonu. Türk Biyokimya Dergisi 2003;28: 45-49.
15. Juretic D, Tadijanovic M. Serum paraoxonase activities in hemodialyzed üremic patient: Cohort study. Croatian Med Journal 2001;42; 146-50.
16. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chem Acta 1978;40: 37-43.
17. Isomaa B, Almgren P, Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24: 683–89.
18. Garin B, Kalix B. Small dense lipoprotein particles and reduced PON1 in patiens with metabolic syndrome. J Clin Endoc Metab 2005;90: 2264-69.
19. Van Himbergen TM, van Tits LJH, Roest M, Stalenhoef AFH. The story of PON1: how an organophosphatehydrolysing enzyme is becoming a player in cardiovascular medicine. Netherlands The Journals of Medicine 2006;64: 34-38.
20. Lucio GC, Annabella V, Toby BC, Clement EF. Modulation of paraoxonase (PON1) activity. Biochemical Pharmacology 2005;69: 541–50.
21. Natalia F, Jordi C. Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General Population. Clinical Chemistry 2003; 49: 1491–97.
22. Sierksma A, van der Gaag MS, van Tol A, James RW, Hendriks HF. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res 2002;26: 1430-35.
23. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999;9: 745-53.
24. Van der Gaag MS, van Tol A, Scheek LM. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999; 147: 405-10.
25. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme’s free thiols. Biochem Biophys Res Commun 1997;236: 289-93.